AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3144300 — intervention group
Group type: COMPARATOR
Intervention: Chlormethiazole 500 mg
Number of subjects: 10
Study 3144300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29605787 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended training (self-training video, website, Moodle platform, intelligent manikin, 45 min instructor presence)
Number of subjects: 129
Study 29605787 — intervention group
Group type: COMPARATOR
Intervention: Control group (face-to-face training based on ERC Guidelines)
Number of subjects: 129
Study 29605787 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended training
Number of subjects: 129
Study 29605787 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study 26685850 — intervention group
Group type: COMPARATOR
Intervention: ProTaper® rotary system
Number of subjects: 78
Study 26685850 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc® system
Number of subjects: 78
Study 25604900 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/day DHEA
Number of subjects: 99
Study 25604900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 24326568 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% solution, applied once daily to the upper eyelid margin for 6 months
Number of subjects: 0
Study 24326568 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% solution
Number of subjects: 0
Study 24326568 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle control)
Number of subjects: 0
Study 22137073 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training plus usual care
Number of subjects: 0
Study 22137073 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 18077316 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)
Number of subjects: 30
Study 18077316 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2) + MPA
Number of subjects: 30
Study 18077316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 30
Study 18077316 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 18077316 — intervention group
Group type: EXPERIMENTAL
Intervention: All hormonal treatments (E(2), E(2) + MPA, Tibolone)
Number of subjects: 30
Study 16518347 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP (4 pmol/kg/min)
Number of subjects: 10
Study 16518347 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP with ET-B receptor antagonist BQ-788 (50 nmol/min)
Number of subjects: 10
Study 16518347 — intervention group
Group type: COMPARATOR
Intervention: Placebo (i.v.)
Number of subjects: 10
Study 16518347 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-788 infusion
Number of subjects: 10
Study 14512076 — intervention group
Group type: EXPERIMENTAL
Intervention: American university students' drinking patterns pamphlet
Number of subjects: 0
Study 14512076 — intervention group
Group type: COMPARATOR
Intervention: Canadian population drinking patterns pamphlet
Number of subjects: 0
Study 14512076 — intervention group
Group type: COMPARATOR
Intervention: Canadian university students' drinking patterns pamphlet
Number of subjects: 0
Study 11053723 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mm tip electrode catheter
Number of subjects: 0
Study 11053723 — intervention group
Group type: COMPARATOR
Intervention: 4-mm tip electrode catheter
Number of subjects: 0
Study 9177879 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns stimulated with FMLP
Number of subjects: 11
Study 9177879 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns stimulated with (Ser‐IL‐8)77
Number of subjects: 11
Study 9177879 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns stimulated with (Ala‐IL‐8)77
Number of subjects: 11
Study 9177879 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns stimulated with Fc gamma RII crosslinking
Number of subjects: 11
Study 9177879 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns after stimulation with FMLP
Number of subjects: 11
Study 9177879 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns after stimulation with C5a
Number of subjects: 11
Study 9177879 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns after stimulation with (Ser‐IL‐8)72
Number of subjects: 11
Study 9177879 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils from patients with burns after stimulation with Fc gamma RII crosslinking
Number of subjects: 11
Study 9177879 — intervention group
Group type: COMPARATOR
Intervention: Neutrophils from patients with burns at discharge
Number of subjects: 11
Study 8358135 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 55
Study 8358135 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine
Number of subjects: 55
Study 8358135 — intervention group
Group type: COMPARATOR
Intervention: Control blocks (not specified)
Number of subjects: 55
Study 8358135 — intervention group
Group type: EXPERIMENTAL
Intervention: Single diagnostic blocks
Number of subjects: 55
Study 3324800 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone treatment
Number of subjects: 19
Study 3324800 — intervention group
Group type: COMPARATOR
Intervention: Saline treatment
Number of subjects: 19
Study 3324800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol intoxication (CPAF group)
Number of subjects: 19
Study 3324800 — intervention group
Group type: COMPARATOR
Intervention: Ethanol intoxication (nonflushing group)
Number of subjects: 19
Study 29932516 — intervention group
Group type: EXPERIMENTAL
Intervention: BWC combined with CBT-D
Number of subjects: 76
Study 29932516 — intervention group
Group type: COMPARATOR
Intervention: CBT-D
Number of subjects: 76
Study 29932516 — intervention group
Group type: COMPARATOR
Intervention: BWC
Number of subjects: 76
Study 29932516 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (BWC, CBT-D, BWC combined with CBT-D)
Number of subjects: 76
Study 26141262 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT (Alutard SQ)
Number of subjects: 24
Study 26141262 — intervention group
Group type: COMPARATOR
Intervention: Open control group
Number of subjects: 24
Study 24281361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT) plus Treatment as Usual (TAU)
Number of subjects: 82
Study 24281361 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 82
Study 23363920 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial services provided by social workers
Number of subjects: 300
Study 19756028 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut consumption (rarely/never, <1, 1, 2-4, 5-6, 7+ servings per week)
Number of subjects: 20224
Study 19756028 — intervention group
Group type: COMPARATOR
Intervention: Nut consumption
Number of subjects: 20224
Study 18251623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (mean daily dose 84.1 mg/day, SD = 54.8; range, 40-200)
Number of subjects: 60
Study 18251623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16825332 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (100 mg for women; 200 mg for men)
Number of subjects: 79
Study 16825332 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Number of subjects: 79
Study 16825332 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate and resistance exercise
Number of subjects: 79
Study 16825332 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 79
Study 16825332 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 79
Study 14657829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular iron
Number of subjects: 5
Study 14657829 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron (3 months)
Number of subjects: 5
Study 14657829 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 5
Study 11016326 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 U AT concentrate
Number of subjects: 85
Study 11016326 — intervention group
Group type: COMPARATOR
Intervention: Additional heparin
Number of subjects: 85
Study 9001875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid 1 g given by intravenous infusion 30 minutes before the operation
Number of subjects: 35
Study 1333962 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine blockade
Number of subjects: 6
Study 1333962 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 6
Study 4017884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin seal used intraoperatively in 19 patients
Number of subjects: 417
Study 4017884 — intervention group
Group type: COMPARATOR
Intervention: Standard care without fibrin seal
Number of subjects: 417
Study 30231106 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine 266 mg
Number of subjects: 69
Study 30231106 — intervention group
Group type: COMPARATOR
Intervention: Control (no liposomal bupivacaine)
Number of subjects: 69
Study 27210851 — intervention group
Group type: COMPARATOR
Intervention: Strengthening training (ST)
Number of subjects: 28
Study 27210851 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening training + whole body vibration training (ST + WBV)
Number of subjects: 28
Study 24886402 — intervention group
Group type: EXPERIMENTAL
Intervention: Day Hospital Mentalization-Based Treatment (MBT-DH)
Number of subjects: 2
Study 24886402 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 2
Study 24886402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness assessment
Number of subjects: 2
Study 23246445 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI at 8°C
Number of subjects: 9
Study 23246445 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI at 15°C
Number of subjects: 9
Study 23246445 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9
Study 23246445 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI at 8°C and CWI at 15°C
Number of subjects: 9
Study 19853892 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge
Number of subjects: 132
Study 19853892 — intervention group
Group type: COMPARATOR
Intervention: Standard hospitalization
Number of subjects: 132
Study 18466359 — intervention group
Group type: EXPERIMENTAL
Intervention: Asimadoline 0.5 mg
Number of subjects: 596
Study 18466359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 596
Study 15911727 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT of 50
Number of subjects: 1201
Study 15911727 — intervention group
Group type: EXPERIMENTAL
Intervention: NNT of 1600
Number of subjects: 1201
Study 15911727 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding lethal disease
Number of subjects: 1201
Study 15911727 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventing stroke
Number of subjects: 1201
Study 15911727 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventing myocardial infarction
Number of subjects: 1201
Study 15911727 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventing hip fracture
Number of subjects: 1201
Study 15911727 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment costs of $37
Number of subjects: 1201
Study 15911727 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment costs of $68
Number of subjects: 1201
Study 15911727 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment costs of $162
Number of subjects: 1201
Study 15911727 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment costs of $589
Number of subjects: 1201
Study 15911727 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation of NNT
Number of subjects: 1201
Study 12822091 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality simulator
Number of subjects: 16
Study 12822091 — intervention group
Group type: COMPARATOR
Intervention: Bedside teaching
Number of subjects: 16
Study 10697395 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (streptokinase or tissue-type plasminogen activator)
Number of subjects: 94
Study 10697395 — intervention group
Group type: COMPARATOR
Intervention: Control group (28 healthy persons)
Number of subjects: 94
Study 10697395 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with anterior AMI
Number of subjects: 94
Study 10697395 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with inferior AMI
Number of subjects: 94
Study 8738616 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic vasovasostomy
Number of subjects: 60
Study 8738616 — intervention group
Group type: COMPARATOR
Intervention: Macroscopic vasovasal anastomosis
Number of subjects: 60
Study 8738616 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 1680422 — intervention group
Group type: EXPERIMENTAL
Intervention: CCPD
Number of subjects: 56
Study 1680422 — intervention group
Group type: COMPARATOR
Intervention: CAPD-Y
Number of subjects: 56
Study 6110093 — intervention group
Group type: EXPERIMENTAL
Intervention: LM24056 at 100 mg
Number of subjects: 23
Study 6110093 — intervention group
Group type: EXPERIMENTAL
Intervention: LM24056 at 200 mg
Number of subjects: 23
Study 6110093 — intervention group
Group type: EXPERIMENTAL
Intervention: LM24056 at 300 mg
Number of subjects: 23
Study 31984963 — intervention group
Group type: EXPERIMENTAL
Intervention: Artmaking with fluid materials (e.g., finger paints)
Number of subjects: 0
Study 31984963 — intervention group
Group type: EXPERIMENTAL
Intervention: Artmaking with less fluid materials (e.g., gouache paint with a brush)
Number of subjects: 0
Study 31984963 — intervention group
Group type: COMPARATOR
Intervention: Music listening before each art making session
Number of subjects: 0
Study 31053990 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-mediated home-based intervention focusing on joint attention, imitation, social and adaptive skills, delivered in five outpatient sessions over 12 weeks.
Number of subjects: 50
Study 31053990 — intervention group
Group type: COMPARATOR
Intervention: Active control group (details not specified).
Number of subjects: 50
Study 27943042 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAFV (Left Atrial Appendage Flow Velocity)
Number of subjects: 120
Study 27943042 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels
Number of subjects: 120
Study 27943042 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAFV
Number of subjects: 120
Study 27943042 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after catheter ablation
Number of subjects: 120
Study 27400910 — intervention group
Group type: EXPERIMENTAL
Intervention: Be Resilient to Breast Cancer (BRBC) program
Number of subjects: 204
Study 25213048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate-vilanterol 100-25 mcg
Number of subjects: 609
Study 25213048 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 mcg
Number of subjects: 609
Study 25213048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study 21918905 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 1 mg per day
Number of subjects: 80
Study 21918905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 19576676 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating rescuers every 1 minute
Number of subjects: 80
Study 19576676 — intervention group
Group type: COMPARATOR
Intervention: Alternating rescuers every 2 minutes
Number of subjects: 80
Study 18156033 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide plus formoterol maintenance and reliever therapy
Number of subjects: 2250
Study 18156033 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose budesonide plus formoterol
Number of subjects: 2250
Study 18156033 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose fluticasone plus salmeterol
Number of subjects: 2250
Study 18156033 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustable regimen of budesonide plus formoterol
Number of subjects: 2250
Study 15167427 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 21
Study 12575620 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative IgE measurement using the CAP-system
Number of subjects: 0
Study 12575620 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative IgE measurement by intensity of fluorescence
Number of subjects: 0
Study 9700784 — intervention group
Group type: EXPERIMENTAL
Intervention: External nasal dilator strip
Number of subjects: 17
Study 9700784 — intervention group
Group type: COMPARATOR
Intervention: Control (without external nasal dilator strip)
Number of subjects: 17
Study 7867676 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 40 mg
Number of subjects: 6
Study 7867676 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 6
Study 7867676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2744909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) 400 mg/day for 13 days
Number of subjects: 24
Study 2744909 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin 300 mg/day for 13 days
Number of subjects: 24
Study 2744909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 105970 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (200 mg qds)
Number of subjects: 26
Study 105970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31773821 — intervention group
Group type: EXPERIMENTAL
Intervention: Amputated limb quadriceps
Number of subjects: 9
Study 31773821 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary torque (MVT) in amputated limb
Number of subjects: 9
Study 31773821 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of torque development (RTD) in amputated limb
Number of subjects: 9
Study 31773821 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural activation in amputated limb
Number of subjects: 9
Study 31773821 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle thickness in amputated limb
Number of subjects: 9
Study 31773821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic contractile properties in amputated limb
Number of subjects: 9
Study 31773821 — intervention group
Group type: COMPARATOR
Intervention: Control limb (intact limb)
Number of subjects: 9
Study 31331772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine
Number of subjects: 0
Study 31331772 — intervention group
Group type: COMPARATOR
Intervention: Mathematical models assuming no latency
Number of subjects: 0
Study 31331772 — intervention group
Group type: COMPARATOR
Intervention: Mathematical models including reactivation of latent infection
Number of subjects: 0
Study 28673765 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate adhesive
Number of subjects: 128
Study 28673765 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adhesive)
Number of subjects: 128
Study 25578128 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 25
Study 25578128 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 25
Study 25578128 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical rhinometry (ORM)
Number of subjects: 25
Study 23969483 — intervention group
Group type: COMPARATOR
Intervention: Full guided parent-delivered CBT (four face-to-face and four telephone sessions)
Number of subjects: 194
Study 23969483 — intervention group
Group type: COMPARATOR
Intervention: Brief guided parent-delivered CBT (two face-to-face and two telephone sessions)
Number of subjects: 194
Study 21625085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal home HD (5-6 times per week)
Number of subjects: 139
Study 21625085 — intervention group
Group type: COMPARATOR
Intervention: Conventional HD (3 times per week)
Number of subjects: 139
Study 21625085 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal home HD (6 times per week)
Number of subjects: 139
Study 19333154 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% lidocaine
Number of subjects: 24
Study 19333154 — intervention group
Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 24
Study 17007869 — intervention group
Group type: EXPERIMENTAL
Intervention: Children aged 6 years and adults
Number of subjects: 0
Study 17007869 — intervention group
Group type: EXPERIMENTAL
Intervention: All age groups (including children aged 4 years)
Number of subjects: 0
Study 14998615 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 5491
Study 14998615 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic men
Number of subjects: 5491
Study 14998615 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic women
Number of subjects: 5491
Study 14998615 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients
Number of subjects: 5491
Study 11741361 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy with coronary angiography/revascularization within 7 days
Number of subjects: 2457
Study 11741361 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive strategy with coronary procedures only when symptoms or severe ischaemia recurred
Number of subjects: 2457
Study 9819646 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAIR sequence at 0.5 Tesla
Number of subjects: 19
Study 9819646 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA (3D-TOF) at 0.5 Tesla
Number of subjects: 19
Study 9819646 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients without SAH)
Number of subjects: 19
Study 8030597 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine 10.8 mg/kg ideal body weight (group 2)
Number of subjects: 20
Study 8030597 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine 50 mg/kg ideal body weight (group 3)
Number of subjects: 20
Study 8030597 — intervention group
Group type: COMPARATOR
Intervention: No taurine (control group)
Number of subjects: 20
Study 2729161 — intervention group
Group type: EXPERIMENTAL
Intervention: PPBG less than 13 mmol/L
Number of subjects: 0
Study 2729161 — intervention group
Group type: EXPERIMENTAL
Intervention: PPBG greater than 13 mmol/L
Number of subjects: 0